Lecanemab Homecare Service
Direct supply and administration of Lecanemab (Leqembi) in a patient’s home, via a homecare delivery service. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoE ε 4) heterozygotes or non-carriers. The service is being offered by UCLH private Healthcare and will be for private patients only.
Buyer
University College London Hospitals NHS FT
Value
£816,000
Published
19 Feb 2025
Closes
26 Mar 2025
Procurement details
Source
Find a Tender
Region
Camden and City of London
Procurement method
Open
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
85149000
Pharmacy services
Lots
Lot 1 Lecanemab Homecare Service
Value not provided
The service requirements for the direct supply and administration of Lecanemab (Leqembi) in a patient’s home, via a homecare delivery service. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoE ε 4) heterozygotes or non-carriers. The service...
Delivery: Inner London - West
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.